Hot off the Forge
-
Forge will be delivering presentations, participating in fireside chats, and taking one-on-one meetings at four September investor conferences.
-
“Forge has proven to be a trusted partner to many gene therapy developers.”
-
Christopher Shilling to represent Forge on the BGTC’s Steering Committee, which will work towards speeding the process of gene therapy…
-
Forge’s presentations at the Meeting of the American Society of Gene and Cell Therapy highlight cell line and plasmid developments.
-
Through this partnership, Forge will help Life Bio advance their innovative cellular rejuvenation technology.
-
As a result of this strategic collaboration, gene therapy clients across the industry will gain access to manufacturing capabilities, drug…
-
Declaration allows Forge to better support clients intending to export gene therapy products for clinical programs in Europe.
-
“We are encouraged by the continued safety and efficacy observed in FBX-101 treated patients. Notably, some of the patients were…
-
“Expanding our leadership team with these strategic hires… supports our vision for growth and the value we provide to our…
-
PRIME designation is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients…
-
Forge will provide services to support Oculogenex’ gene therapy program for patients with dry age-related macular degeneration (AMD) toward clinical…
-
Among other updates, Forge to discuss adding plasmid DNA manufacturing to suite of gene therapy offerings.